Recite me link

1. Within your Trust, how many patients, in the most recent 12-month period for which data are available, have received anti-VEGF treatment for the first time (i.e., excluding patients who previously had any anti-VEGF therapy)?

2. Of these first-time patients, please provide a breakdown by the treatments listed below:
Aflibercept
Brolucizumab
Dexamethasone
Ranibizumab
All other anti-VEGF treatments

3. Of these first-time patients, how many were treated for Wet Age-Related Macular Degeneration (wAMD) by each treatment?
Aflibercept
Brolucizumab
Dexamethasone
Ranibizumab
All Other anti-VEGF treatments

Download response Anti-VEGF treatment. 240720